A
Akebia Therapeutics, Inc. (AKBA)
NCM – Real Time Price. Currency in USD
1.34
-0.05 (-3.60%)
At close: Mar 27, 2026, 4:00 PM EDT
1.34
0.00 (0.00%)
After-hours: Mar 27, 2026, 7:55 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
1.34
-0.05 (-3.60%)
At close: Mar 27, 2026, 4:00 PM EDT
1.34
0.00 (0.00%)
After-hours: Mar 27, 2026, 7:55 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.55 | 2.52 | 8.0 | |
| Quick ratio | 1.46 | 1.78 | 7.0 | |
| Debt to Equity | 6.63 | -0.80 | 2.0 | |
| Debt to Assets | 0.57 | 0.73 | 4.0 | |
| Interest coverage | -1.77 | -13.90 | 1.0 | |
| Weighted average score | 4.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 292M | 195M | 160M | 236M | 236M |
| Gross Profit | 205M | 119M | 91M | 195M | 195M |
| Operating Income | -65M | -46M | -50M | 23M | 23M |
| Net Income | -94M | -52M | -69M | -5M | -5M |
| EBITDA | -30M | -4M | -9M | 25M | 25M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -9.38 | -200 | 1.0 |
| Next quarter | -13.46 | N/A | 1.0 |
| Current year | -2.02 | -210 | 1.0 |
| Next year | -16.65 | -132.26 | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -1.94 | -2367.4 | 999 | 10.81 | 4.8 |
| Y/Y | 23.93 | 46.31 | 50 | 795.14 | 10 |
| 3y average | -1.22 | 34.51 | 40.4 | 86.81 | 7.8 |
| 5y average | 1.24 | 39.31 | 45.96 | 40.59 | 8.3 |
| Weighted average score | 7.7 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $216.3M significantly exceeds cash reserves ($186.5M), raising financial stability concerns
Total current assets $253.0M exceed Total current liabilities $162.9M, highlighting excellent liquidity
Debt-to-equity ratio (6.6) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (-1.8x) is dangerously low, suggesting debt repayment risks
The company generates positive free cash flow $31.1M, supporting its financial health